A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20

作者：Lopez Sara Mata; Hammond James J; Rig**y Madison B; Balog Alvarez Cynthia J; Kornegay Joe N; Nghiem Peter P^*

来源：Skeletal Muscle, 2018, 8(1): 16.

DOI：10.1186/s13395-018-0162-1

• Whole genome sequencing
• Next-generation sequencing
• DMD
• Duchenne muscular dystrophy
• Dystrophin
• CXMD
• Animal model
• Canine

Background: Boys with Duchenne muscular dystrophy (DMD) have DMD gene mutations, with associated loss of the dystrophin protein and progressive muscle degeneration and weakness. Corticosteroids and palliative support are currently the best treatment options. The long-term benefits of recently approved compounds such as eteplirsen and ataluren remain to be seen. Dogs with naturally occurring dystrophinopathies show progressive disease akin to that of DMD. Accordingly, canine DMD models are useful for studies of pathogenesis and preclinical therapy development. A dystrophin-deficient, male border collie dog was evaluated at the age of 5 months for progressive muscle weakness and dysphagia.
Case presentation: Dramatically increased serum creatine kinase levels (41,520 U/L; normal range 59-895 U/L) were seen on a biochemistry panel. Histopathologic changes characteristic of dystrophinopathy were seen. Dystrophin was absent in the skeletal muscle on immunofluorescence microscopy and western blot. Whole genome sequencing, polymerase chain reaction, and Sanger sequencing revealed a frameshift, single nucleotide deletion in canine DMD exon 20, position 27,626,466 (c. 2841delT mRNA), resulting in a stop codon six nucleotides downstream. Semen was archived for future line perpetuation.
Conclusions: This spontaneous canine dystrophinopathy occurred due to a novel mutation in the minor DMD mutation hotspot (between exons 2 through 20). Perpetuating this line could allow for preclinical testing of genetic therapies targeted to this area of the DMD gene.

• 出版日期2018-5-29